What is Alentis Therapeutics?
Alentis Therapeutics operates at the intersection of precision medicine and advanced immunology, focusing on the development of innovative therapies that target Claudin-1. The company's pipeline is anchored by its anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies, most notably the ADC candidate ALE.P02 for squamous cancers and the monoclonal antibody lixudebart for organ fibrosis. By identifying and validating Claudin-1 as a critical therapeutic target, Alentis has established a unique market position, moving beyond traditional treatment modalities to address the underlying mechanisms of disease progression in both cancer and fibrotic conditions.
How much funding has Alentis Therapeutics raised?
Alentis Therapeutics has raised a total of $365.9M across 4 funding rounds:
Series A
$12.5M
Series B
$67M
Series C
$105M
Series D
$181.4M
Series A (2019): $12.5M with participation from German High-Tech Gründerfonds, BPI France, BioMedPartners, BB Pureos Bioventures, and Schroder Adveq
Series B (2021): $67M led by Bpifrance, Schroders Capital, BB Pureos Bioventures, Jeito, BioMedPartners, High-Tech Gründerfonds, and Morningside Venture Investments
Series C (2023): $105M supported by Novo Holdings, Jeito, and RA Capital Management
Series D (2024): $181.4M featuring OrbiMed and Novo Holdings
Key Investors in Alentis Therapeutics
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with a deep expertise in life sciences.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on long-term value creation in the life science industry.
Jeito
A global investment company with a patient-benefit driven approach that finances and accelerates the development of ground-breaking medical innovation in Europe and the United States.
What's next for Alentis Therapeutics?
With the successful completion of its latest financing round, Alentis Therapeutics is poised to transition its lead candidates through critical clinical milestones. The strategic deployment of this capital will likely focus on expanding patient enrollment in ongoing trials and refining the manufacturing processes for its ADC platform. As the company matures, the focus will shift toward data readouts that could validate its therapeutic approach, potentially setting the stage for future licensing agreements or strategic partnerships with larger pharmaceutical entities. The continued support from specialized healthcare investors suggests a long-term commitment to building a sustainable, high-impact biotech enterprise capable of delivering transformative patient outcomes.
See full Alentis Therapeutics company page
